FDA Rationale for Polymyxin Breakpoints for Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp.

Rationale for Polymyxin Breakpoints for Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp.

Source: FDA Center for Drug Evaluation and Research - What's New - January 17, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news